Chang, et al., Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (−)-2′,3′-thiacytidine in the Inhibition of Hepatitis B Virus Replication, Journal of Biological Chemistry, vol. 267(20), 13938-13942 (1992). (Jul., 1992). |
Davisson, et al., Synthesis of Nucleotide 5′-Diphosphates from 5′-O-Tosyl Nucleosides, J. Org. Chem., 52(9), 1794-1801 (1987). |
Du J et al, Synthesis, “Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides,” J. of Med. Chem., (40)19, 2991-2993 (1997). (Sep. 12, 1997). |
Furman, et al., “The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (−) and (+) Enantiomers of cis-5-Fluro-1[2-Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine” Antimicrobial Agents and Chemotherapy, 36(12) 2686-2692 (1992). (Dec., 1992). |
Hoard, et al., Conversion of Mono-and Oligodeoxyribonucleotides to 5′-Triphosphates, J. Am. Chem. Soc., 87(8), 1785-1788 (1965). (Apr.-Jun., 1965). |
Antonin Holy “Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2′-deoxy-L-Ribonucleosides of the Pyrimidine Series,” Collect. Czech. Chem. Commun. (1972), 37(12), 4072-87. (Dec., 1972). |
Hostetler, K.Y., D.D. Richman, D.A. Carson, L.M. Stuhmiller, G.M. T. van Wijk, and H. van den Bosch. 1992. Antimicrob Agents Chemother. 36:2025-2029 (Sep., 1992). |
Hostetler, K.Y., L.M. Stuhmiller, H.B. Lenting, H. van den Bosch, and D.D. Richman. 1990. J. Biol. Chem. 265:6112-7. (Apr. 15, 1990). |
Verri, Biochem. J. (1997), 328(1), 317-20). (Nov. 15, 1997). |
Gosselin, G.; Bergogne, M.-C.; Imbach, J.-L., “Synthesis and Antiviral Evaluation of -L-Xylofuranosyl Nucleosides of the Five Naturally Occuring Nucleic Acid Bases”, Journal of Heterocyclic Chemistry, 1993, 30 (Oct.-Nov.), 1229-1233. |
Bloch, et al. (J. Med. Chem. (1967), 10(5), 908-12). (Sep., 1967). |
Kucera, L.S., N. Lyer, E. Leake, A. Raben, Modest E.J., D. L. W., and C. Piantadosi. 1990. AIDS Res Hum Retroviruses. 6:491-501; (Issue No. 4; (X Apr., 1990). |
R. Jones and N. Bischfberger, Mini Review: Nucleotide prodrugs, Antiviral Research, 27, 1-17 (1995). |
Imai et al., J. Org. Chem., 34(6), 1547-1550 (Jun. 1969). |
Nakayama, C., and Saneyoshi, M., Synthetic Nucleosides and Nucleotides. XX. Synthesis of Various 1—Xylofuranosyl-5-Alkyluracils and Related Nucleosides. Nucleosides. Nucleotides, 1, 139-146 (1982). |
Maga et al. , Biochem. J. (1993), 294(2), 381-5. (Sep. 1, 1993). |
Robins, M.J., et al., Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2′-Deoxynucleosides. J. Am. Chem. Soc. 105, 4059-4065 (1983). |
Korba and Milman, A cell culture assay for compounds which inhibit hepatitis B virus replication, Antiviral Res., 15:217 1991. (Issue No. 1, Jan., 1991). |
Spadari, J. Med. Chem. (1992), 35(22), 4214-20. |
Morris S. Zedeck et al. Pseudomonas testosteroni, Mol. Phys. (1967), 3(4), 386-95. |
Robins, M. J.; Khwaja, T. A.; Robins, R. K. J. Org. Chem. 1970, 35, 636-639 (Issue No. 3; Mar., 1970). |
Saneyoshi, M., and Satoh, E., Synthetic Nucleosides and Nucleotides. XIII. Stannic Chloride Catalyzed Ribosylation of Several 6-Substituted Purines. Chem; Pharm. Bull., 27, 2518-2521 (1979). |
Tyrsted et al. (Biochim. Biophys. Acta (1968), 155(2), 619-22). |
Verri et al. Mol. Pharmacol. (1997), 51(1), 132-138 (Jan., 1997). |
Zhang, W., and Robins, M. J., Removal of Silyl Protecting Groups from Hydroxyl Functions with Ammonium Fluoride in Methanol. Tetrahedron Lett., 33, 1177-1180 (192). (Feb. 25, 1992). |
Norbeck, Tetrahedron Letters 30 (46), 6246 (1989). |
Robins, “Selective Deoxygenation and Modification at C2′ of Nucleosides,” pp. 1-4 in Nucleic Acids Research Symposium Series, vol. No. 11, Kyoto, Japan, Nov. 24-26, 1982, A. E. Pritchard (ed.), IRL Press, Ltd., Oxford, England, 1982; see also Chemical Abstracts, 98, Abstract No. 107670u (1982) supplied by applicant as PTO-1449 ref. CA-2 in parent application 09/371,747.* |
Lin et al. (I), “Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents,” Tetrahedron, 51(4), 1055-1068 (1995).* |
Lin et al. (II), “Design and Synthesis of 2′, 3′-Dideoxy-2′, 3′-didehydro-β-L-cytidine (β-L-d4C) and 2′, 3′-Dideoxy-2′, 3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) In Vitro,” Journal of Medicinal Chemistry, 39(9), 1757-1759 (Apr. 26, 1996).* |
von Janta-Lipinski et al., “Newly Synthesized L-Enantiomers of 3′-Fluoro-Modified β-2′-Deoxyribonucleoside 5′-Triphosphates Inhibit Hepatitis B DNA Polymerase But Not the Five Cellular DNA Polymerases α, β, γ, δ, and ε Nor HIV-1 Reverse Transcriptase,” Journal of Medicinal Chemistry, 41(12), 2040-2046 (Jun. 4, 1996).* |
Mansour et al., “Sterochemical Aspects of the Anti-HCMV Activity of Cytidine Nucleoside Analogues,” Antiviral Chemistry & Chemotherapy, 6(3), 138-142 (1995).* |
Verri et al., “Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues,” Biochemical Journal, 328(1), 317-320 (Nov. 15, 1997).* |
Spadari et al., “L-Thymidine Is Phosphorylated by Herpes Simplex Type 1 Thymidine Kinase and Inhibits Viral Growth,” Journal of Medicinal Chemistry, 35(22), 1214-1220 (1992)††.* |
Bryant et al., “Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection,” Antimicrobial Agents and Chemotherapy, 45(1), 229-235 (Jan., 2001)††. |